Freedom of Information Request ID
7409
Date of response
June 2022
I have a freedom of information query. In the past 3 months, how many non-small cell lung cancer (NSCLC) patients were treated with:
Afatinib
Alectinib
Amivantamab
Atezolizumab monotherapy
Atezolizumab with chemotherapy
Brigatinib
Ceritinib
Crizotinib
Dacomitinib
Dabrafenib with Trametinib
Durvalumab
Erlotinib
Gefitinib
Lorlatinib
Mobocertinib
Nintedanib with Docetaxel
Nivolumab
Osimertinib
Pembrolizumab monotherapy
Pembrolizumab with chemotherapy
Pemetrexed with Carboplatin/Cisplatin
Sotorasib
Tepotinib
Vinorelbine with Carboplatin/Cisplatin
Any other active systemic anti-cancer therapy (SACT)
Palliative care only
Medway NHS Foundation Trust regret that we are unable to answer your request as this data is not collated.
The Trust’s Business Intelligence team collate patient numbers for medical conditions, but do not collate data around the treatments patients receive.
Therefore, we can confirm that from 01/03/2022 to 13/06/2022, there were a total of 116 lung cancer patients treated by the Trust, however, coding does not distinguish which of these patients are ‘non-small cell’.
The Trust’s Pharmacy team collate data relating to drugs issued but do not record the indication for the use of the drug or whether it was administered to the patient. Please see below data held for all drugs from BNF chapter 8 – Immune System + Malignant Disease, for any indication not just NSCLC. If the drug is not listed it is because it hasn’t been issued from Pharmacy.
FOI Requests
The Freedom of Information Act 2000 provides people with a right of access to a wide range of information held by public authorities, including the NHS.
FOI Disclosure Log
A collection of the most common FOI requests we have received and responded to.
